Results 71 to 80 of about 86,601 (293)

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

British Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis, Leiah J. Brigitha, Lidwien M. Hanff, Alwin D. R. Huitema, Inge M. van der Sluis, Meta H. M. Diekstra   +5 more
wiley   +1 more source

Diffuse large B-cell lymphoma in the uterus with unexpected manifestations: a case report

Journal of Medical Case Reports
Background Lymphoid neoplasm is a common disease, arising from lymphoid cells. It is divided into Hodgkin lymphoma and non-Hodgkin lymphoma. Non-Hodgkin lymphoma can be intranodular or extranodular, which happens in 25% of primary cases.
Kenana Tawashi, Tuka Hamasho, Mustafa Al-Hussien, Ameen Ammar   +3 more
doaj   +1 more source

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

British Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon, Hinke Huisman‐Siebinga, Shelby Barnett, Paul Wetherell, Pamela Kearns, Brenda Gibson, Nicholas Heaney, Owen Smith, André Baruchel, Arnaud Petit, Andrew Moore, Kayode Ogungbenro, Alwin D. R. Huitema, Gareth J. Veal   +13 more
wiley   +1 more source

Diagnosis validity of AgNOR staining for differentaing non-Hodgkin lymphoma from reactive hyperplasia

مجله دانشگاه علوم پزشکی گرگان, 2005
Background&Objective: There are different methods including H&E, imonhistochemstry, flu cytometry, AgNOR staining for differentiation reactive hyperplasia from lymphoma.
Zh.Torabizade (MD), F.Naghshvar (MD), O.Emadian (MD)   +2 more
doaj  

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Non-Hogkins lymphoma ′masquerading′ as pott′s disease in a 13-year old boy: A case report

Sahel Medical Journal, 2010
Lymphomas are malignant neoplasms of the lymphoid lineage which are broadly classified as either Hodgkin disease or as non-Hodgkin lymphoma (NHL).
O A Adegboye
doaj  

Primary Dural Lymphoma: Clinical Cases and Literature Review

Case Reports in Medicine, 2020
Primary dural lymphoma (PDL) is an extranodal non-Hodgkin lymphoma that accounts for less than 1% of all central nervous system lymphomas. Primary dural lymphoma grows from the dura mater, and it is often diagnosed as meningioma or acute subdural ...
M. Dobran, R. Paracino, F. Mancini, D. Nasi   +3 more
doaj   +1 more source

Staging Non-Hodgkin Lymphoma [PDF]

CA: A Cancer Journal for Clinicians, 2005
Non-Hodgkin Lymphomas are always treatable and frequently curable malignancies. However, choosing the most appropriate therapy requires accurate diagnosis and a careful staging evaluation. New patients with non-Hodgkin Lymphoma should have their tumors classified using the World Health Organization classification.
openaire   +2 more sources

Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV

International Journal of Cancer, EarlyView.
What's New? This large nation‐wide cohort study provides a comprehensive 20‐year analysis of cancer trends among people living with HIV in France, highlighting persistent excess risks for virus‐related cancers despite effective antiretroviral therapy and immune restoration.
Sophie Grabar, Paula Lakrout, Valérie Potard, Aurélien Belot, Jacques Cadranel, Christine Jacomet, Christine Katlama, Esaïe Marshall, Olivier Lambotte, Romain Palich, Sylvie Ronot‐Bregigeon, Jean‐Philippe Spano, Anne‐Marie Bouvier, Alain Makinson, Dominique Costagliola   +14 more
wiley   +1 more source

Immune Thrombocytopenia in a Child with T Cell Lymphoblastic Lymphoma

Case Reports in Hematology, 2016
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma.
Kayo Tokeji, Sachi Sakaguchi, Tomoko Kurimoto, Junya Fujimura, Toshiaki Shimizu   +4 more
doaj   +1 more source